RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Sinopharm Group Co - Stock

Sinopharm Group Co Stocks 2024

Sinopharm Group Co Stocks

3.12 B

Ticker

1099.HK

ISIN

CNE100000FN7

WKN

A0N99U

In 2024, Sinopharm Group Co had 3.12 B outstanding stocks, a 0% change from the 3.12 B stocks in the previous year.

The Sinopharm Group Co Stocks history

YEARNUMBER OF STOCKS (undefined CNY)
2028e3.12
2027e3.12
2026e3.12
2025e3.12
2024e3.12
20233.12
20223.12
20213.12
20203.11
20192.97
20182.97
20172.97
20162.77
20152.77
20142.59
20132.52
20122.4
20112.36
20102.27
20091.81
20081.64
20071.64
20061.64

Sinopharm Group Co shares outstanding

The number of shares was Sinopharm Group Co in 2023 — This indicates how many shares 3.121 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Sinopharm Group Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Sinopharm Group Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Sinopharm Group Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Sinopharm Group Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Sinopharm Group Co Aktienanalyse

What does Sinopharm Group Co do?

Sinopharm Group Co Ltd is one of the largest Chinese companies in the healthcare industry and was founded in 1998. With its headquarters in Beijing, it has been a significant player in the global healthcare sector for many years and operates in various business areas. The company's history dates back to the 1940s when the original company, China National Pharmaceutical Industry Corporation, was founded. It was later transformed into China National Pharmaceutical Group and eventually renamed Sinopharm Group. Sinopharm's business model is designed to promote healthcare in China while expanding internationally. The company's key business areas include pharmaceutical research and development, drug manufacturing, and the import and export of pharmaceutical products. Overall, Sinopharm Group operates in various sectors, including the production of biological drugs, diagnostic products, medical devices, and medical consumables. Additionally, the company is involved in providing healthcare services such as hospital management and health tourism. An important part of Sinopharm's business is the export of drugs and other medical products. The company has established a global presence and maintains businesses and collaborations with companies in Asia, Europe, North America, and Africa. Furthermore, Sinopharm Group has established several subsidiaries to focus on specialized markets and products better. On the product side, Sinopharm offers a wide range of medications, health products, and medical devices. Some of the most well-known products include anti-cancer drugs, diabetes medications, vaccines, and blood products. The company also invests in research and development of new drugs and is involved in numerous clinical trials. The success of Sinopharm is also based on its close collaboration with the Chinese government. The company works closely with local and national authorities to meet the demand for healthcare products and services in China. The Chinese government also supports the company and promotes its expansion into other countries. Overall, Sinopharm Group has become a significant player in the global healthcare industry in recent years. The company has a strong presence in China and a growing international presence. With a wide range of products and services and a strong focus on research and development, Sinopharm Group is well-positioned to continue growing and adapting to the demands of the healthcare sector. Sinopharm Group Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Sinopharm Group Co's Shares Outstanding

Sinopharm Group Co's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Sinopharm Group Co’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Sinopharm Group Co’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Sinopharm Group Co’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Sinopharm Group Co Stock

How many stocks are there of Sinopharm Group Co?

The current number of stocks of Sinopharm Group Co is 3.12 B undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Sinopharm Group Co are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Sinopharm Group Co evolved in recent years?

The number of shares of Sinopharm Group Co has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Sinopharm Group Co as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Sinopharm Group Co?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Sinopharm Group Co pay?

Over the past 12 months, Sinopharm Group Co paid a dividend of 0.9 CNY . This corresponds to a dividend yield of about 4.5 %. For the coming 12 months, Sinopharm Group Co is expected to pay a dividend of 0.98 CNY.

What is the dividend yield of Sinopharm Group Co?

The current dividend yield of Sinopharm Group Co is 4.5 %.

When does Sinopharm Group Co pay dividends?

Sinopharm Group Co pays a quarterly dividend. This is distributed in the months of July, July, July, July.

How secure is the dividend of Sinopharm Group Co?

Sinopharm Group Co paid dividends every year for the past 19 years.

What is the dividend of Sinopharm Group Co?

For the upcoming 12 months, dividends amounting to 0.98 CNY are expected. This corresponds to a dividend yield of 4.88 %.

In which sector is Sinopharm Group Co located?

Sinopharm Group Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sinopharm Group Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sinopharm Group Co from 8/13/2024 amounting to 0.87 CNY, you needed to have the stock in your portfolio before the ex-date on 6/17/2024.

When did Sinopharm Group Co pay the last dividend?

The last dividend was paid out on 8/13/2024.

What was the dividend of Sinopharm Group Co in the year 2023?

In the year 2023, Sinopharm Group Co distributed 0.872 CNY as dividends.

In which currency does Sinopharm Group Co pay out the dividend?

The dividends of Sinopharm Group Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Sinopharm Group Co

Our stock analysis for Sinopharm Group Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sinopharm Group Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.